Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a faster steroid taper spare sarcoidosis patients from harmful side effects?

NCT ID NCT07498842

Recruiting now Disease control Sponsor: Royal Brompton & Harefield NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two steroid-tapering schedules for people with stable sarcoidosis who have been on prednisolone for at least six months. The goal is to see which approach helps more patients cut their dose by at least half without causing a flare-up. Researchers will also monitor side effects, muscle strength, and body composition changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
prednisolone
What this could lead to
If successful, this could establish a safe, standard method for reducing steroid use in sarcoidosis, lowering long-term side effects like diabetes and bone loss.
What could go wrong
This is a small, early-phase study with only 100 participants. The faster taper may cause disease flares or withdrawal symptoms, and results may not apply to all sarcoidosis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOIDOSIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Royal Brompton Hospital

    RECRUITING

    London, SW36NP, United Kingdom

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.